Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population

NCT05155605 is registered in ClinicalTrials.gov with GRAIL, Inc. as lead sponsor.

NCT NCT05155605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05155605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
Lead sponsor
GRAIL, Inc.
Phase
Not applicable
Overall status
Active, not recruiting
Start date
December 8, 2021
Completion date
April 30, 2028
Enrollment
35,883 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, early detection of cancer